Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enavogliflozin - Daewoong

Drug Profile

Enavogliflozin - Daewoong

Alternative Names: Dapagliflozin; DWP-16001; DWP16001 drug A; DWP16001 drug B; DWP16001 drug C; Envlo; ODP 9401

Latest Information Update: 06 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antihypercalcaemics; Antihyperglycaemics; Benzofurans; Cyclopropanes; Heart failure therapies; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Heart failure

Most Recent Events

  • 04 Dec 2023 m8 Pharmaceuticals has been acquired by Acino
  • 27 Nov 2023 Daewoong Pharmaceutical plans a phase III trial in Type 2 diabetes mellitus (In adults, In the elderly) (PO, Tablet) in December 2023 (NCT06141980)
  • 01 Nov 2023 Launched for Type 2 diabetes mellitus (Combination therapy, In the elderly, In adults) in South Korea prior to November 2023 (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top